美国 · SEC FORM 4
Cullinan Therapeutics, Inc.
CGEM · Nasdaq · CIK 0001789972 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
11 同一窗口内观察到的 Form 4 交易行
5 sales · 6 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-10-28 · Lynx1 Capital Management LP; Nichols Weston · $1.4M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Michaelson JenniferChief Scientific Officer
○▼○▼○▼○▼
SUMER JACQUELYN LChief Legal Officer
○
Fenton Mary KayChief Financial Officer
○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-10-28 · Lynx1 Capital Management LP; Nichols Weston.
近期 Form 4 活动
1买入
28卖出
11其他 Form 4 交易行
30SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出5 sale line(s) · 仅供背景
其他6 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,634,127
- 上期报告
- 9,629,017
- 日均成交量
- 1,505,393
- 回补天数
- 5.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-28 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share | 165,667 | USD 8.40 | USD 1,391,603 | SEC 申报 ↗ |
| 2025-10-17 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 32,217 | USD 7.84 | USD 252,581 | SEC 申报 ↗ |
| 2025-10-16 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 150,000 | USD 8.86 | USD 1,329,000 | SEC 申报 ↗ |
| 2025-10-15 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 51,500 | USD 7.94 | USD 408,910 | SEC 申报 ↗ |
| 2025-10-14 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 15,032 | USD 7.59 | USD 114,093 | SEC 申报 ↗ |
| 2025-10-10 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 277,298 | USD 7.36 | USD 2,040,913 | SEC 申报 ↗ |
| 2025-10-09 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 626,043 | USD 6.70 | USD 4,194,488 | SEC 申报 ↗ |
| 2025-10-08 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 556,300 | USD 6.46 | USD 3,593,698 | SEC 申报 ↗ |
| 2022-06-06 | AHMED NADIM | 买入 (P) | Common Stock | 8,090 | USD 12.40 | USD 100,316 | SEC 申报 ↗ |
| 2022-06-01 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock | 751,396 | USD 11.00 | USD 8,265,356 | SEC 申报 ↗ |
| 2022-05-13 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock | 109,900 | USD 9.14 | USD 1,004,486 | SEC 申报 ↗ |
| 2022-05-12 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock | 1,000,000 | USD 9.06 | USD 9,060,000 | SEC 申报 ↗ |
| 2022-04-01 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock | 276,000 | USD 10.75 | USD 2,967,000 | SEC 申报 ↗ |
| 2021-01-12 | Trigilio Jeffrey | 买入 (P) | Common Stock | 2,250 | USD 21.00 | USD 47,250 | SEC 申报 ↗ |
| 2021-01-12 | MPM Oncology Impact Management GP LLC; MPM Oncology Impact Management LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P. | 买入 (P) | Common Stock | 300,000 | USD 21.00 | USD 6,300,000 | SEC 申报 ↗ |
Form 4 申报证据
40 transaction lines in the latest 365-day window; 308 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Michaelson Jennifer | 卖出 (S) | Common Stock | 8,000 | USD 21.57 | USD 172,560 | SEC 申报 ↗ |
| 2026-09-08 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 4,000 | USD 4.30 | USD 17,200 | SEC 申报 ↗ |
| 2026-08-13 | Michaelson Jennifer | 卖出 (S) | Common Stock | 30,000 | USD 20.26 | USD 607,800 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Michaelson Jennifer | 卖出 (S) | Common Stock | 8,000 | USD 21.57 | USD 172,560 | SEC 申报 ↗ |
| 2026-09-08 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 4,000 | USD 4.30 | USD 17,200 | SEC 申报 ↗ |
| 2026-08-13 | Michaelson Jennifer | 卖出 (S) | Common Stock | 30,000 | USD 20.26 | USD 607,800 | SEC 申报 ↗ |
| 2026-08-13 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 30,000 | USD 4.30 | USD 129,000 | SEC 申报 ↗ |
| 2026-07-06 | Michaelson Jennifer | 卖出 (S) | Common Stock | 8,000 | USD 17.82 | USD 142,560 | SEC 申报 ↗ |
| 2026-07-06 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 4,000 | USD 4.30 | USD 17,200 | SEC 申报 ↗ |
| 2026-06-30 | SUMER JACQUELYN L | 奖励／授予 (A) | Common Stock | 2,470 | USD 8.60 | USD 21,242 | SEC 申报 ↗ |
| 2026-06-30 | Fenton Mary Kay | 奖励／授予 (A) | Common Stock | 1,541 | USD 8.60 | USD 13,253 | SEC 申报 ↗ |
| 2026-05-05 | Michaelson Jennifer | 卖出 (S) | Common Stock | 8,000 | USD 14.62 | USD 116,996 | SEC 申报 ↗ |
| 2026-05-05 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 4,000 | USD 4.30 | USD 17,200 | SEC 申报 ↗ |
| 2026-03-05 | Michaelson Jennifer | 卖出 (S) | Common Stock | 8,000 | USD 15.68 | USD 125,440 | SEC 申报 ↗ |
| 2026-03-05 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 4,000 | USD 4.30 | USD 17,200 | SEC 申报 ↗ |
| 2026-02-25 | Michaelson Jennifer | 卖出 (S) | Common Stock | 1,780 | USD 14.14 | USD 25,169 | SEC 申报 ↗ |
| 2026-02-24 | SUMER JACQUELYN L | 卖出 (S) | Common Stock | 3,601 | USD 14.47 | USD 52,106 | SEC 申报 ↗ |
| 2026-02-24 | Michaelson Jennifer | 卖出 (S) | Common Stock | 3,601 | USD 14.47 | USD 52,106 | SEC 申报 ↗ |
| 2026-02-24 | Jones Jeffrey Alan | 卖出 (S) | Common Stock | 4,582 | USD 14.47 | USD 66,302 | SEC 申报 ↗ |
| 2026-02-24 | AHMED NADIM | 卖出 (S) | Common Stock | 13,515 | USD 14.47 | USD 195,562 | SEC 申报 ↗ |
| 2026-02-23 | Michaelson Jennifer | 卖出 (S) | Common Stock | 1,752 | USD 13.99 | USD 24,510 | SEC 申报 ↗ |
| 2026-02-20 | SUMER JACQUELYN L | 卖出 (S) | Common Stock | 3,742 | USD 13.62 | USD 50,966 | SEC 申报 ↗ |
| 2026-02-20 | Michaelson Jennifer | 卖出 (S) | Common Stock | 11,742 | USD 14.08 | USD 165,366 | SEC 申报 ↗ |
| 2026-02-20 | Michaelson Jennifer | 期权行权／转换 (M) | Common Stock | 8,000 | USD 4.30 | USD 34,400 | SEC 申报 ↗ |
| 2026-02-20 | Jones Jeffrey Alan | 卖出 (S) | Common Stock | 4,982 | USD 13.62 | USD 67,855 | SEC 申报 ↗ |
| 2026-02-20 | Fenton Mary Kay | 卖出 (S) | Common Stock | 4,398 | USD 13.62 | USD 59,901 | SEC 申报 ↗ |
| 2026-02-20 | AHMED NADIM | 卖出 (S) | Common Stock | 16,381 | USD 13.62 | USD 223,109 | SEC 申报 ↗ |
| 2026-02-18 | Michaelson Jennifer | 奖励／授予 (A) | Common Stock | 57,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-18 | Fenton Mary Kay | 奖励／授予 (A) | Common Stock | 68,750 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-12 | Michaelson Jennifer | 卖出 (S) | Common Stock | 416 | USD 12.03 | USD 5,004 | SEC 申报 ↗ |
| 2026-01-22 | Michaelson Jennifer | 卖出 (S) | Common Stock | 4,000 | USD 12.30 | USD 49,200 | SEC 申报 ↗ |
| 2025-12-31 | Fenton Mary Kay | 奖励／授予 (A) | Common Stock | 27 | USD 6.49 | USD 175 | SEC 申报 ↗ |
| 2025-12-23 | AHMED NADIM | 卖出 (S) | Common Stock | 9,922 | USD 10.01 | USD 99,319 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CGEM |
| CIK | 0001789972 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 308 transaction lines from 2021-01-07 to 2026-09-08 25 P purchase lines · 193 S sale lines · 90 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.